Investigational drug · Phase 2
rivogenlecleucel
Also called: BPX-501 T cells, BPX-501
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Leukemia, Acute Myeloid (AML), Child.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 12, 2022 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
9
Any phase or sponsor naming "rivogenlecleucel"
First trial start
2013
Mar 2013
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "rivogenlecleucel", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Lymphoblastic Leukemia
- Myelodysplastic Syndromes
- Leukemia, Acute Myeloid (AML), Child
- Lymphoma, Non-Hodgkin
- Primary Immune Deficiency Disorder
- Osteopetrosis
- Cytopenia
- Hemoglobinopathy in Children
- Anemia, Aplastic
- Acute Myelogenous Leukemia
Approved drugs for the same conditions: Acute lymphoblastic leukemia · Lymphoma (non-Hodgkin) · Myelodysplastic syndromes · Anemia · Hematology and blood cancers · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "rivogenlecleucel" as an intervention, largest first.
- Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell TransplantTerminated
Bellicum PharmaceuticalsIndustry
NCT02065869 · 187 participants · Start Apr 2014 · Primary completion Jun 2020
Drug: BPX-501 T cells; Rimiducid · For: Acute Lymphoblastic Leukemia; Leukemia, Acute Myeloid (AML), Child; Lymphoma, Non-Hodgkin and 10 more
Sites: Roma, Italy; London, United Kingdom; Newcastle upon Tyne, United Kingdom · 4 sites in all
Bellicum PharmaceuticalsIndustry
NCT03733249 · 187 participants · Start Jan 2017 · Primary completion Jun 30, 2020
Drug: Rimiducid; rivogenlecleucel · For: Acute Lymphoblastic Leukemia; Leukemia, Acute Myeloid (AML), Child; Lymphoma, Non-Hodgkin and 9 more
Sites: Rome, Italy
- Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell TransplantActive, not recruiting
Bellicum PharmaceuticalsIndustry
NCT03301168 · 120 participants (planned) · Start Apr 2014 · Primary completion May 11, 2021
Drug: BPX-501 T cells; Rimiducid · For: Acute Lymphoblastic Leukemia; Leukemia, Acute Myeloid (AML), Child; Lymphoma, Non-Hodgkin and 6 more
Sites: Los Angeles, California; Palo Alto, California; Washington D.C., District of Columbia · 10 sites in all
- Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell TransplantActive, not recruiting
Bellicum PharmaceuticalsIndustry
NCT01744223 · 36 participants (planned) · Start Mar 2013 · Primary completion Oct 9, 2019
Drug: BPX-501 dose 1; Rimiducid and 3 more · For: Acute Lymphoblastic Leukemia; Acute Myelogenous Leukemia; Lymphoma and 1 more
Sites: Atlanta, Georgia; Buffalo, New York; New York, New York · 8 sites in all
- Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo TransplantActive, not recruiting
Bellicum PharmaceuticalsIndustry
NCT03459170 · 15 participants (planned) · Start Feb 1, 2018 · Primary completion Sep 2022
Drug: BPX-501 T cells; rimiducid · For: Hematologic Malignancy
Sites: Pavia, Italy; Rome, Italy; Turin, Italy
- Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDSPivotal-lookingTerminated
Bellicum PharmaceuticalsIndustry
NCT03699475 · 1 participants · Start Dec 27, 2018 · Primary completion Jul 23, 2019
Drug: rivogenlecleucel; rimiducid and 1 more · For: Acute Myeloid Leukemia; Myelodysplastic Syndromes
Sites: Nashville, Tennessee; San Antonio, Texas
- Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCTWithdrawn
Bellicum PharmaceuticalsIndustry
NCT02786485 · 0 participants · Start May 2016 · Primary completion Dec 2018
Drug: rivogenlecleucel; Rimiducid · For: Leukemia; Myelodysplastic Syndromes; Lymphomas and 2 more
Fred Hutchinson Cancer CenterAcademic, hospital or other
NCT03807063 · 0 participants · Start Jan 2, 2020 · Primary completion Dec 31, 2020
Drug: Rivogenlecleucel; Rimiducid · For: Acute Bilineal Leukemia; Myelodysplastic/Myeloproliferative Neoplasm; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable and 9 more
Sites: Seattle, Washington
- BPX-501 T Cells Infused Post Stem Cell Transplant in Pediatrics With Non-Malignant Disorders Ineligible for BPU004 StudyNo longer available
Bellicum PharmaceuticalsIndustry
NCT03639844
Drug: rivogenlecleucel; rimiducid · For: Hurler Syndrome; Inherited Metabolic Disorder; Lysosomal Storage Disorder and 2 more
Sites: Los Angeles, California; Palo Alto, California
Newest research
PubMed records naming it or its code names, newest first.
- Haploidentical transplantation: An optimal platform for graft manipulation and cellular therapies.
Astigarraga CC, Mpms K, Iovino L, et al. · Blood Rev 2025
- BPX-501 T cells interfere with minimal residual disease evaluation of B-cell acute lymphoblastic leukemia.
Amro Elshoury, Wallace PK, Borowitz MJ, et al. · Bone Marrow Transplant 2018
Also in development for Acute Lymphoblastic Leukemia
- MK-1045CN-201Phase 36 trials
Merck & Co. · Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, Follicular
- RimiducidAP1903Phase 23 trials
Bellicum Pharmaceuticals · Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Leukemia, Acute Myeloid (AML), Child
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.